Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Absci Corporation (ABSI:NASDAQ), powered by AI.
Absci Corporation is currently trading at $6.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Absci Corporation on Alpha Lenz.
Absci Corporation's P/E ratio is -8.1.
“Absci Corporation trades at a P/E of -8.1 (undervalued) with modest ROE of -62.5%.”
Ask for details →Absci Corporation operates at the cutting edge of synthetic biology and drug discovery. As a biotechnology company, its primary function is to harness the power of artificial intelligence and synthetic biology to expedite the discovery and development of therapeutic proteins. By integrating machine learning with its proprietary synthetic biology platform, Absci aims to revolutionize how pharmaceuticals are designed, developed, and manufactured. This innovative approach holds significant promise for the healthcare and biotech industries, including enabling more efficient drug development processes and potentially uncovering new therapeutic pathways. Based in Vancouver, Washington, Absci Corporation serves as a vital player in the quest to transform biopharmaceuticals, ensuring more rapid and cost-effective delivery of medicines. The company's commitment to innovation situates it as a transformative entity within the global healthcare and life sciences sectors, offering scalable solutions that could set new benchmarks in the industry.
“Absci Corporation trades at a P/E of -8.1 (undervalued) with modest ROE of -62.5%.”
Ask for details →Absci Corporation (ticker: ABSI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 156 employees. Market cap is $930M.
The current price is $6.8 with a P/E ratio of -8.07x and P/B of 4.91x.
ROE is -62.50% and operating margin is -4479.21%. Annual revenue is $3M.